SAN CLEMENTE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Sofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in...
COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate...
With multiple 7-figure exits, John Gulyas will help lead Safety Shot in its ongoing efforts to become a leading wellness...
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial...
Monotherapy activity with PD-L1-targeting MT-6402 in Head and Neck Cancer; Unique pharmacodynamic effects with CTLA-4 targeting MT-8421 in on-going phase...
The Phase 1b trial of VLS-01 investigates the pharmacokinetics, pharmacodynamics, safety and tolerability of atai’s proprietary, optimized oral transmucosal formulation...
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD...
VANCOUVER, British Columbia, March 04, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device...
Bobcat mRNATM technology is a novel linear mRNA platform able to encode large proteins Data showed restoration of muscular function...
WATERTOWN, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the formation...
EMERYVILLE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic...
-The Stroke Advisory Board brings together distinguished experts in neurology and stroke to support the advancement of its neural exosome...
PHOENIX, AZ / ACCESSWIRE / March 4, 2024 / RushNet, Inc (OTC PINK:RSHN), (the "Company") announced today the appointment of...
Ethics and regulatory approvals finalized for world-first take-home use of a psychedelic medicine MB22001 in placebo-controlled trial in depressed patients...
STOCKHOLM, SE / ACCESSWIRE / March 04, 2024 / PMD Device Solutions (STO:PROMO) (FRA:8T0) Redeye assigns a base-case valuation of...
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
WASHINGTON, DC / ACCESSWIRE / March 3, 2024 / Association executives from the American Pharmacists Association (APhA), the National Community...
PALO ALTO, Calif., March 02, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), an innovative revenue-generating company focused...
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of...